Bimagrumab: the muscle-sparing partner for GLP-1s

Key takeaways

• It targets the muscle problem directly. GLP-1 weight loss costs lean mass as well as fat; bimagrumab is an antibody designed to build muscle and cut fat at the same time .
• The mechanism is a released brake. Bimagrumab blocks activin type II receptors, the signaling brake that normally limits skeletal muscle growth, which drives muscle hypertrophy and fat loss .
• BELIEVE is the headline trial. Adding bimagrumab to semaglutide shifted about 92.3 percent of weight loss to fat at week 48, versus about 71.1 percent on semaglutide alone, and largely preserved lean mass .
• On its own, it does something unusual. In an earlier trial in adults with type 2 diabetes and obesity, bimagrumab cut fat mass by about 20.5 percent while increasing lean mass by about 3.6 percent .
• Read the trial design honestly. In BELIEVE, the bimagrumab-versus-placebo backbone was blinded, but the semaglutide layer was open-label, so it is not a clean double-blind head-to-head. It is investigational and not FDA-approved .

Skip to:

• The muscle problem with GLP-1 weight loss
• What bimagrumab is and how it works
• What the trials show
• The honest catch in the BELIEVE design
• The bottom line

The muscle problem with GLP-1 weight loss

When you lose weight fast on a GLP-1, not all of what leaves is fat. A meaningful share is lean mass, the muscle that supports strength, metabolism, and long-term function. That lean-mass loss is one of the genuine downsides of rapid weight loss, and it is the gap bimagrumab is built to fill (the wider issue is covered in GLP-1 and muscle loss).

Most strategies to protect muscle during weight loss are behavioral: enough protein and resistance training. Bimagrumab is a pharmacological attempt at the same goal, and that is what makes it interesting. Instead of just slowing muscle loss, it is designed to actively build muscle while the GLP-1 strips the fat .

What bimagrumab is and how it works

Bimagrumab is a fully human monoclonal antibody, given by intravenous infusion, that blocks the activin type II receptors (ActRIIA and ActRIIB) on muscle . Those receptors are part of a signaling system that normally puts a brake on muscle growth. Block the receptors, and you release the brake: muscle grows, and at the same time the body sheds fat .

That dual effect is why it pairs naturally with a GLP-1. The GLP-1 drives the appetite suppression and the overall weight loss; bimagrumab biases the body composition of that loss toward fat and protects muscle. In preclinical work, blocking these receptors preserved muscle mass and enhanced fat loss specifically during GLP-1 receptor agonist treatment, which is the exact scenario the combination trial set out to test .

What the trials show

The combination evidence comes from BELIEVE, a phase 2 randomized trial of 507 adults with obesity assigned across nine groups (placebo, bimagrumab, semaglutide, and combinations) for 48 weeks, with an extension to 72 weeks . The total weight loss was real (about 17.8 kg on the high-dose combination versus 14.2 kg on semaglutide 2.4 mg alone and 3.3 kg on placebo at week 48), but the more telling result is what that weight was made of.

Bimagrumab also has a striking solo result from an earlier study. In a phase 2 trial in adults with type 2 diabetes and obesity, bimagrumab alone cut fat mass by about 20.5 percent (around 7.5 kg) while increasing lean mass by about 3.6 percent (around 1.7 kg), and lowered HbA1c by about 0.76 percentage points, over 48 weeks . Losing fat while gaining muscle is the kind of result diet and drugs rarely produce together.

The honest catch in the BELIEVE design

An evidence-first reading has to flag how BELIEVE was built. The bimagrumab-versus-placebo comparison was double-blind, because bimagrumab is an intravenous infusion that could be matched with a placebo infusion. But the trial used commercially available semaglutide pens, which could not be blinded, so the semaglutide layer was open-label and self-injected .

That caveat does not erase the signal; it sizes it. The muscle-sparing effect showed up consistently and is mechanistically plausible, but phase 2 with an open-label arm is a reason to be interested, not a reason to treat it as settled.

The bottom line

Bimagrumab is an experimental antibody that blocks a muscle-growth brake, and its appeal is not bigger weight loss but better weight loss. Added to semaglutide in the phase 2 BELIEVE trial, it shifted about 92 percent of the lost weight to fat and largely spared muscle, and on its own it has cut fat while adding lean mass .

The honest framing is that this is a promising idea at phase 2, with an open-label semaglutide layer in its key trial and no FDA approval yet . If the muscle-sparing effect holds up in larger blinded trials, it could change what good weight loss looks like. For now it is one of the most interesting things to watch in the GLP-1 space, not something you can use.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 3 entries, all primary canon (the Nature Medicine phase 2 BELIEVE trial, a JAMA Network Open phase 2 trial in type 2 diabetes, and a Molecular Metabolism mechanism study), last reviewed 2026-06-28.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Body-recomp simulator overview - Public overview of the Pro body-recomposition simulator.